Acer Therapeutics Inc (NASDAQ:ACER)

18.75
Delayed Data
As of Apr 20
 -0.19 / -1.00%
Today’s Change
5.70
Today|||52-Week Range
22.63
+35.38%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$145.9M

Company Description

Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with critical unmet medical need. Its products include Edsivo and ACER-001. Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling in September 2017 and is headquartered in Cambridge, MA.

Contact Information

Acer Therapeutics, Inc.
One Gateway Center
Newton Massachusetts 02458
P:(844) 902-6100
Investor Relations:

Employees

Shareholders

Other institutional6.92%
Individual stakeholders57.25%
Mutual fund holders0.48%

Top Executives

Christopher SchellingPresident, Chief Executive Officer & Director
Harry S. PalminChief Financial Officer
William T. AndrewsChief Medical Officer
Jefferson DavisChief Business Officer
Kim TharaldsenSenior Marketing Director